Gilead battles Congress, European regulators over hep C drug price
July 11, 2014 at 16:55 PM EDT
Gilead Sciences Inc. is fighting on two regulatory fronts in its efforts to sell its $1,000-a-pill hepatitis C drug Sovaldi...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.